Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a breathing trick plus mild zaps strengthen brain pathways in MS?

NCT ID NCT06413602

Knowledge-focused Sponsor: Shirley Ryan AbilityLab Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether combining a special breathing technique (called acute intermittent hypoxia, or AIH) with mild electrical stimulation of leg muscles can boost brain-to-muscle signals in people with relapsing forms of multiple sclerosis. About 40 participants will have their ankle strength and brain responses measured after each type of stimulation, alone and together. The goal is to see if the combination works better than either one alone, which could lead to better rehabilitation therapies in the future.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2024

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for persons with MS: * Diagnosis of relapsing form of MS * Expanded Disability Status Scale (EDSS) score of at least 3 and no more than 6.5 * Relapse free for at least 1 year * Age ≥18 years and ≤75 years * No change in Dalfampridine dose at least 2 months prior to enrollment Exclusion Criteria for persons with MS: * Uncontrolled hypertension or hypotension (outside 140/90 and 90/60 mmHg) * History of epilepsy or seizures Inclusion Criteria for uninjured controls: * Age ≥18 years and ≤75 years * Safe to participate in TMS (TMS questionnaire) Exclusion Criteria for uninjured controls: * Uncontrolled hypertension or hypotension (outside 140/90 and 90/60 mmHg) * History of epilepsy or seizures Exclusion criteria to TMS participation for persons with MS and uninjured controls: * Uncontrolled medical problems affecting the lungs (pulmonary diseases including chronic obstructive pulmonary disease), the heart (cardiovascular diseases) or the musculoskeletal system (orthopedic diseases) * Premorbid, ongoing major depression or psychosis, altered cognitive status * History of stroke * Metal in head (e.g., surgical clips, shrapnel) * History of seizures or epilepsy diagnosis * Receiving drugs acting primarily on the central nervous system, which lower the seizure threshold such as antipsychotic drugs (chlorpromazine, clozapine) or tricyclic antidepressants * Surgery to the head * Any non-MS related neurological diseases * Illnesses that may have caused brain injury * Unexplained frequent or severe headaches * Pregnancy in females * Implanted devices (e.g., pacemakers, medical pumps, brain stimulators) * Unable to participate in TMS

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple sclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic progressive multiple sclerosis Hypoxia multiple sclerosis relapsing-remitting multiple sclerosis secondary progressive multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple sclerosis Multiple sclerosis, relapsing-remitting Multiple sclerosis, secondary progressive

Contacts and locations

Locations

  • Shirley Ryan AbilityLab

    Chicago, Illinois, 60611, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.